Phase 1Status unknownAge-related condition
Stem Cell Therapy for Type 2 Diabetes Mellitus
A Open Labeled and Self Controlled, Safety/Efficacy Assessed Pilot Study on Transplantation Therapy Using Bone Marrow Mesenchymal Stem Cells for Insulin Resistance of Type 2 Diabetes Mellitus
- Sponsor
- Cellonis Biotechnology Co. Ltd. (Industry)
- Enrolment
- 24 planned
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- mesenchymal stem cells
- Ages
- adults, older adults
- Registry
- NCT01142050
Full record on ClinicalTrials.gov
From the registry
The purpose of the study is to evaluate the efficacy and safety in the treatment of Insulin Resistance of Type 2 Diabetes Mellitus with Bone Marrow Mesenchymal Stem Cells.
Primary outcomes
- ITT; insulin dosage; Hemoglobin A1c; Fast blood glucose (FBG) and Postmeal blood glucose (PBG); C-peptide levels; Serum Insulin levels;
History
Study completion
Primary completion
Started
Registered